- Home
- CGNT vs AKBA Comparison
CGNT vs AKBA Comparison
Compare CGNT & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- AKBA
- Stock Information
- Founded
- CGNT 2020
- AKBA 2007
- Country
- CGNT Israel
- AKBA United States
- Employees
- CGNT N/A
- AKBA N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- CGNT Technology
- AKBA Health Care
- Exchange
- CGNT Nasdaq
- AKBA Nasdaq
- Market Cap
- CGNT 617.3M
- AKBA 729.1M
- IPO Year
- CGNT N/A
- AKBA 2014
- Fundamental
- Price
- CGNT $8.42
- AKBA $2.08
- Analyst Decision
- CGNT Buy
- AKBA Strong Buy
- Analyst Count
- CGNT 2
- AKBA 6
- Target Price
- CGNT $14.00
- AKBA $6.25
- AVG Volume (30 Days)
- CGNT 289.4K
- AKBA 4.5M
- Earning Date
- CGNT 12-10-2025
- AKBA 11-10-2025
- Dividend Yield
- CGNT N/A
- AKBA N/A
- EPS Growth
- CGNT N/A
- AKBA N/A
- EPS
- CGNT N/A
- AKBA N/A
- Revenue
- CGNT $376,566,000.00
- AKBA $203,733,000.00
- Revenue This Year
- CGNT $15.30
- AKBA $53.38
- Revenue Next Year
- CGNT $11.30
- AKBA $30.53
- P/E Ratio
- CGNT N/A
- AKBA N/A
- Revenue Growth
- CGNT 14.04
- AKBA 16.75
- 52 Week Low
- CGNT $6.45
- AKBA $1.52
- 52 Week High
- CGNT $11.66
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- CGNT 49.89
- AKBA 30.38
- Support Level
- CGNT $8.24
- AKBA $2.07
- Resistance Level
- CGNT $8.99
- AKBA $3.19
- Average True Range (ATR)
- CGNT 0.23
- AKBA 0.15
- MACD
- CGNT 0.04
- AKBA -0.09
- Stochastic Oscillator
- CGNT 43.96
- AKBA 0.44
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.